SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 28, 2003
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
Delaware |
(State or other jurisdiction of incorporation)
000-23265 | 94-3267443 | |
(Commission file Number) | (IRS Employer ID Number) |
8540 Colonnade Center Drive, Suite 501, Raleigh, North Carolina 27615 |
(Address of principal executive offices) (Zip Code) |
Registrant’s telephone number, including area code (919) 862-1000
|
Item 5. Other Events and Regulation FD Disclosure
Salix Pharmaceuticals, Ltd. announced that it will present at the Thomas Weisel Partners annual healthcare conference – Healthcare Tailwinds 2003 – in Boston, Massachusetts on Thursday, September 4 at 2:40 p.m., Eastern Time. A copy of this press release is attached.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. | Description | |
99.1 | Press release dated August 28, 2003 of Salix Pharmaceuticals, Ltd., announcing that it will present at the Thomas Weisel Partners annual healthcare conference – Healthcare Tailwinds 2003 – in Boston, Massachusetts on Thursday, September 4 at 2:40 p.m., Eastern Time. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALIX PHARMACEUTICALS, LTD. | ||||||||
Date: August 28, 2003 | By: | /s/ Adam C. Derbyshire | ||||||
Adam C. Derbyshire Senior Vice President and Chief Financial Officer |